Barclays PLC Tg Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 347,057 shares of TGTX stock, worth $10.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

347,057

Previous 139,334 149.08%

Holding current value

$10.3 Million

Previous $2.48 Million 227.43%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$17.21 - $25.28 $3.57 Million - $5.25 Million	207,723 Added 149.08%	347,057 $8.12 Million
Q2 2024 Aug 14, 2024	SELL	$13.32 - $19.19 $227,052 - $327,112	-17,046 Reduced 10.9%	139,334 $2.48 Million
Q1 2024 May 15, 2024	SELL	$13.02 - $21.3 $3.54 Million - $5.79 Million	-271,633 Reduced 63.46%	156,380 $2.38 Million
Q4 2023 Feb 15, 2024	SELL	$6.68 - $18.81 $64,321 - $181,121	-9,629 Reduced 2.2%	428,013 $7.31 Million
Q3 2023 Nov 07, 2023	SELL	$8.36 - $26.5 $379,878 - $1.2 Million	-45,440 Reduced 9.41%	437,642 $3.66 Million
Q2 2023 Aug 03, 2023	SELL	$15.48 - $35.0 $4.75 Million - $10.7 Million	-307,011 Reduced 38.86%	483,082 $12 Million
Q1 2023 May 04, 2023	BUY	$10.23 - $19.34 $2.8 Million - $5.3 Million	274,125 Added 53.13%	790,093 $11.9 Million
Q4 2022 Feb 13, 2023	SELL	$5.01 - $11.83 $381,566 - $900,984	-76,161 Reduced 12.86%	515,968 $6.1 Million
Q3 2022 Nov 03, 2022	BUY	$4.57 - $8.4 $1.2 Million - $2.2 Million	262,360 Added 79.56%	592,129 $3.51 Million
Q2 2022 Aug 12, 2022	BUY	$3.74 - $10.66 $708,647 - $2.02 Million	189,478 Added 135.06%	329,769 $1.4 Million
Q1 2022 May 16, 2022	SELL	$7.81 - $20.45 $609,992 - $1.6 Million	-78,104 Reduced 35.76%	140,291 $1.33 Million
Q4 2021 Feb 14, 2022	BUY	$15.2 - $35.51 $1.8 Million - $4.2 Million	118,164 Added 117.89%	218,395 $4.15 Million
Q3 2021 Nov 09, 2021	BUY	$21.78 - $40.45 $1.65 Million - $3.06 Million	75,588 Added 306.73%	100,231 $3.34 Million
Q2 2021 Aug 13, 2021	SELL	$32.5 - $48.96 $3.14 Million - $4.73 Million	-96,666 Reduced 79.69%	24,643 $956,000
Q1 2021 May 13, 2021	BUY	$41.61 - $54.3 $2.5 Million - $3.26 Million	60,120 Added 98.25%	121,309 $5.85 Million
Q4 2020 Feb 11, 2021	SELL	$25.27 - $54.9 $10.6 Million - $23.1 Million	-420,827 Reduced 87.31%	61,189 $3.18 Million
Q3 2020 Nov 12, 2020	SELL	$18.49 - $27.24 $8.17 Million - $12 Million	-441,933 Reduced 47.83%	482,016 $12.9 Million
Q2 2020 Aug 12, 2020	BUY	$8.9 - $21.84 $560,967 - $1.38 Million	63,030 Added 7.32%	923,949 $18 Million
Q1 2020 May 13, 2020	BUY	$7.14 - $15.99 $481,928 - $1.08 Million	67,497 Added 8.51%	860,919 $8.47 Million
Q4 2019 Feb 10, 2020	BUY	$5.1 - $11.2 $3.22 Million - $7.07 Million	631,210 Added 389.13%	793,422 $8.81 Million
Q3 2019 Nov 14, 2019	BUY	$5.38 - $8.99 $518,895 - $867,076	96,449 Added 146.66%	162,212 $910,000
Q2 2019 Aug 14, 2019	BUY	$6.27 - $8.65 $299,216 - $412,795	47,722 Added 264.52%	65,763 $569,000
Q1 2019 May 15, 2019	SELL	$4.02 - $8.04 $133,532 - $267,064	-33,217 Reduced 64.8%	18,041 $145,000
Q4 2018 Feb 14, 2019	BUY	$3.44 - $5.76 $90,736 - $151,931	26,377 Added 106.01%	51,258 $210,000
Q3 2018 Nov 14, 2018	BUY	$5.15 - $14.0 $78,784 - $214,172	15,298 Added 159.64%	24,881 $140,000
Q2 2018 Aug 14, 2018	SELL	$12.5 - $15.0 $171,512 - $205,815	-13,721 Reduced 58.88%	9,583 $126,000
Q1 2018 May 15, 2018	BUY	$8.7 - $16.8 $104,861 - $202,490	12,053 Added 107.13%	23,304 $331,000
Q4 2017 Feb 14, 2018	SELL	$7.35 - $12.3 $107,824 - $180,441	-14,670 Reduced 56.6%	11,251 $93,000
Q3 2017 Nov 14, 2017	BUY	$10.0 - $12.7 $259,210 - $329,196	25,921	25,921 $307,000

Others Institutions Holding TGTX

# of Institutions

338

Shares Held

88.3M

Call Options Held

2.35M

Put Options Held

1.7M

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.29B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account